NasdaqGS:REGNBiotechs
Is There an Opportunity in Regeneron After $1 Billion Immunology Collaboration With Sanofi?
Thinking about what to do with Regeneron Pharmaceuticals stock right now? You are not alone. With a price tag near $589, and a recent uptick of about 3% over the last month, it is the kind of stock that gives investors something to talk about. Year to date, the story has not been as cheery, with shares sliding nearly 18% and trailing some biotech peers. But when you dig a bit deeper into the fundamentals, the narrative starts to shift from worry to opportunity.
Regeneron is not your average...